Indy Hematology Review Presentation Archive 2023 State of the Art: 2023: Emerging Therapies in Hematologic Malignancies – Ruemu E. Birhiray, MD Improving Outcomes with Current Therapies in Acute Myeloid Leukemia and Acute Promyelocytic Leukemia: What we Recommend in 2023 – Martin Tallman, MD Apollo and The Indianapolis Oracle: Prognostication and Treatment of Myelodysplastic Syndromes – Richard Stone, MD Treatment Goals in Chronic Myeloid Leukemia: Managing Resistance, Recurrence and Discontinuation – Richard Larson, MD Emerging and Current Treatment of Multiple Myeloma: What Should We Know and What Should We Do – Kenneth Anderson, MD Hematopoietic Transplantation and Cellular Therapies – Richard Childs, MD Managing the Benign Hematology Consult: Treatment Recommendations for Coagulopathy, Cytosis and Cytopenia – Craig Kessler, MD, MACP Myelofibrosis Chronic and Blast Phase: 2023 Algorithms for Risk Stratification and Treatment – Ayalew Tefferi, MD Polycythemia Vera, Philadelphia Chromosome Negative Myeloproliferative and FGFR Mutant Myeloid Neoplasms – Angela Fleischman, MD, PhD Current Controversies and Recommendations for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: The Indy Hematology Review Recommendations for 2023 – Wendy Stock, MD, MA Emerging Therapy for Relapsed and Refractory Chronic Lymphocytic Leukemia – William Wierda, MD, PhD Annual Steven Coutre Chronic Lymphocytic Leukemia Memorial Lecture: Therapeutic Options in CLL in 2023: Choosing Wisely: Initial Therapy in CLL – Jennifer Woyach, MD Jumping On a Moving Train: Emerging and Current Treatment for Hodgkin’s Lymphoma – Matthew Lunning D.O., FACP Advancing Therapeutic Outcomes in Aggressive B and T Cell Lymphomas – Tycel Phillips, MD Beyond Hyperviscosity: 80 Years and Counting, Treatment of Waldenstrom’s Macroglobulinemia – Steven Treon, MD, MA, PhD, FACP, FRCP To Transplant or Not When Minimal Residual Disease has been Achieved as Initial Therapy for Multiple Myeloma Monitoring and Rescuing the MRD Negative Patient with Multiple Myeloma After Initial Therapy – Joseph Mikhael MD, MEd, FRCPC, FACP The Great Debate: Controversies in The Initial Therapy of Multiple Myeloma: Transplanting the MRD Negative Myeloma Patients for a Deeper Remission After Initial Therapy – Saad Usmani, MD, MBA, FACP
